Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
N/ANon-phased studies
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Recruiting1
Active, not recruiting1
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (25.0%)
N/A3 (75.0%)

Trials by Status

recruiting125%
active_not_recruiting125%
not_yet_recruiting125%
unknown125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_2

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

NCT06175390
not_yet_recruitingnot_applicable

68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma

NCT06911021
recruitingnot_applicable

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

NCT06790264
unknownnot_applicable

Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma

NCT05339113

Clinical Trials (4)

Showing 4 of 4 trials
NCT06175390Phase 2

Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

Active Not Recruiting
NCT06911021Not Applicable

68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma

Not Yet Recruiting
NCT06790264Not Applicable

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

Recruiting
NCT05339113Not Applicable

Comparison of [68Ga]GaFAPI-46 PET/CT and [18F]FDG PET/CT Findings in Breast Carcinoma

Unknown

All 4 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
4